Indication
Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.
Loading your page…
Loading your page…
Muscular Atrophy, Spinal
Marketing Authorisation Holder: Roche Registration GmbH
EMA Authorisation: 26/03/2021
INN: risdiplam
AI Drug & Interaction Analysis
Free account required
Ask Osler about Evrysdi: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.